SCHEMBL3036495

SCHEMBL3036495

CCN(CC1CCCC1)c1ccc(F)cc1C=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 5/20 0.38
GRIN2A Q12879 5/20 0.38
ALDH1A3 P47895 1/20 0.38
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH3A1 P30838 1/20 0.35
RAB9A P51151 2/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.34
PKM P14618 1/20 0.34
GRIN1 Q05586 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
SSTR3 P32745 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046946 0.90 ALDH1A1 (0.39) GRIA2GRIN2AALDH1A3ALDH1A1L3MBTL1
SCHEMBL3041872 0.85 CNR1 (0.40) GRIA2GRIN2AALDH1A3ALDH1A1L3MBTL1
SCHEMBL3041869 0.85 ALDH1A1 (0.35) GRIA2GRIN2AALDH1A3ALDH1A1L3MBTL1
SCHEMBL3043756 0.84 ALDH1A3 (0.43) ALDH1A3ALDH1A1L3MBTL1HTTNPSR1
SCHEMBL3046479 0.84 CSNK1D (0.36) ALDH1A3ALDH1A1L3MBTL1ALDH3A1RAB9A
SCHEMBL3046454 0.82 ALDH1A1 (0.43) ALDH1A3ALDH1A1L3MBTL1HTTRAB9A
SCHEMBL3043759 0.81 SRC (0.38) ALDH1A3ALDH1A1L3MBTL1ALDH3A1SLC6A2
SCHEMBL3036195 0.79 ERN1 (0.40) GRIA2GRIN2AALDH1A1L3MBTL1POLB
SCHEMBL3545615 0.77 CNR1 (0.33) ALDH1A3ALDH1A1L3MBTL1ALDH3A1RAB9A
SCHEMBL3539336 0.77 NPC1 (0.34) ALDH1A3ALDH1A1L3MBTL1ALDH3A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2149563-B9 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND KOWA CO (JP) 2015-04-22 EP disclosed
EP-2149563-B1 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND KOWA CO (JP) 2015-01-07 EP disclosed
CN-101679309-B Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound KOWA CO 2012-02-29 CN disclosed
CN-101679309-A Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound KOWA CO 2010-03-24 CN disclosed
US-7659271-B2 Pyrimidine compound having dibenzylamine structure and medicament comprising the same KOWA COMPANY, LTD. (JP) 2010-02-09 US disclosed
EP-2149563-A1 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND Kowa Company. Ltd. (JP) 2010-02-03 EP disclosed
US-20090082352-A1 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) KOWA COMPANY, LTD. (JP) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082352-A1 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) CETP, NPC1L1, MTTP GRIA2 3588/4885GRIN2A 3874/4885ALDH1A3 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.